Analysts anticipate Beauty Health Co (recently rebranded to SkinHealth Systems) will report Q2 2026 revenue of $74.45 million and a loss per share of $0.04, as the stock trades near $0.69 against an average analyst target of $1.34. The primary narrative for this quarter is the company's strategic pivot toward a 'utilization-based' model, focusing on high-margin consumables revenue to drive path-to-profitability.
This shift follows a challenging period of corporate rebranding and executive turnover aimed at stabilizing the global HydraFacial installed base and resolving past platform execution issues. Investors are searching for evidence that the transition from upfront device sales to recurring revenue is successfully offsetting macroeconomic headwinds and competitive pressures in the medical aesthetics market.